

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/157417/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Aquilanti, Elisa, Kageler, Lauren, Watson, Jacqueline, Baird, Duncan M , Jones, Rhiannon E, Hodges, Marie, Szegletes, Zsofia M, Doench, John G, Strathdee, Craig A, McFaline Figueroa, Jose Ricardo, Ligon, Keith, Beck, Matthew, Wen, Patrick Y and Meyerson, Matthew 2023. Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume. *Neuro-Oncology* 25 (7) , pp. 1275-1285. 10.1093/neuonc/noad024

Publishers page: <http://dx.doi.org/10.1093/neuonc/noad024>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Telomerase inhibition is an effective therapeutic strategy in *TERT* promoter-mutant glioblastomas models with low tumor burden

Elisa Aquilanti^{1,2}, Lauren Kageler², Jacqueline Watson², Duncan M. Baird³, Rhiannon E. Jones³, Marie Hodges³, Zsofia M. Szegletes⁴, John G. Doench⁴, Craig A. Strathdee², Jose Ricardo McFaline Figueroa¹, Keith Ligon^{2,5}, Matthew Beck², Patrick Y. Wen¹, Matthew Meyerson^{1,2,6}

¹Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

²Cancer Program, Broad Institute, Cambridge, Massachusetts, USA

³Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

⁴Genetic Perturbation Platform, Broad Institute, Cambridge, Massachusetts, USA

⁵Department of Oncologic Pathology, Brigham and Women's Hospital, Boston Children's Hospital, Dana Farber Cancer Institute, Boston, MA, USA

⁶Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA

Running title: Low tumor burden glioblastomas respond to telomerase loss

Key words: Telomerase, glioblastoma, targeted therapy, adjuvant therapy, tumor burden, target validation

Corresponding author: Matthew Meyerson, M.D., Ph.D., matthew_meyerson@dfci.harvard.edu
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115

Conflicts of interest: P.W.: Research Support: Agios, Astra Zeneca/Medimmune, Beigene, Celgene, Eli Lilly, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncocutics, Vascular Biogenics, VBI Vaccines. Advisory Board: Agios, Astra Zeneca, Bayer,

Boston Pharmaceuticals, CNS Pharmaceuticals, Elevate Bio Immunomic Therapeutics, Invax, Karyopharm, Merck, Novartis, Nuvation Bio, Vascular Biogenics, VBI Vaccines, Voyager, QED, Celularity, Sapience. J.G.D.: consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo, and Pfizer; consults for and has equity in Tango Therapeutics; serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GSK; receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology. M.M. is the scientific advisory board chair of Isabl; consults for Bayer, DelveBio and Interline; is an inventor of patents licensed to LabCorp and Bayer; and receives research funding from Bayer and Janssen.

Authorship: E.A., P.W. and M.M. generated the idea for the study. E.A., J.W. and L.K. executed most of the experimental work. D.B., R.J. and M.H. provided advice and expertise on telomere length measurement methods. Z.M.S. and J.G.D. developed the dox-inducible system. C.A.S. developed the overexpression construct. K.L. provided the glioblastoma neurospheres. M.B. helped with in vivo experiments. J.R.M.F. helped with CRISPR knockdown glioblastoma neurospheres. E.A. and L.K. wrote the manuscript. M.M supervised the work and edited the manuscript.

Word count: 6978

Abstract

Background: Glioblastoma is among the deadliest of all cancers, with 5-year survival rates of only 6%. Glioblastoma targeted therapeutics have been challenging to develop due to significant inter- and intra-tumoral heterogeneity. *TERT* promoter mutations are the most common known clonal oncogenic mutations in glioblastoma. Telomerase is therefore considered to be a promising therapeutic target against this tumor. However, an important limitation of this strategy is that cell death does not occur immediately after telomerase ablation, but rather after several cell divisions required to reach critically short telomeres. We therefore hypothesize that telomerase inhibition would only be effective in low tumor burden glioblastomas.

Methods: We used CRISPR interference to knock down *TERT* expression in *TERT* promoter-mutant glioblastoma cell lines and patient derived models. We then measured viability using serial proliferation assays. We also assessed for features of telomere crisis by measuring telomere length and chromatin bridge formation. Lastly, we used a doxycycline-inducible CRISPR interference system to knock down *TERT* expression *in vivo* early and late in the tumor formation process.

Results: Upon *TERT* inactivation, glioblastoma cells lose their proliferative ability over time and exhibit evidence of telomere crisis with telomere shortening and chromatin bridge formation. *In vivo*, tumor formation is only inhibited when *TERT* knockdown is induced shortly after tumor implantation, but not when tumor burden is high.

Conclusions: Our results support the idea that telomerase inhibition would be most effective at treating glioblastomas with low tumor burden, for example in the adjuvant setting after surgical debulking and chemoradiation.

Key points:

1. *TERT* knockdown leads to a reduction in proliferation of *TERT* promoter-mutant glioblastomas
2. *TERT* loss only leads to prolonged survival *in vivo* if initiated in animals with low tumor burden

Importance of the study

Given the high prevalence and clonal nature of *TERT* promoter mutations in glioblastoma, telomerase is considered a promising therapeutic target for this deadly cancer. Prior studies have validated this hypothesis, demonstrating that knockout of the transcription factor GABPA, which selectively binds to the mutant *TERT* promoter, as well as base editing-mediated correction of *TERT* promoter mutations, are selectively toxic to *TERT* promoter mutant glioblastomas. However, an important limitation of this strategy is that cancer cell death upon telomerase inhibition only occurs after multiple cell divisions. For this reason, it is important to define the appropriate clinical setting that would maximize therapeutic efficacy of telomerase inhibitors. In this study, we use CRISPR interference to demonstrate that *TERT* promoter-mutant glioblastoma cells are sensitive to telomerase inhibition and undergo telomere crisis. Furthermore, we demonstrate that telomerase inhibition *in vivo* is only effective if initiated shortly after tumor implantation, supporting the idea that telomerase inhibition would be a suitable therapeutic strategy for glioblastoma patients with low tumor burden.

Introduction

Glioblastoma is an aggressive cancer in dire need of therapeutic progress. Despite extensive research efforts, standard therapies for this tumor have not changed substantially in over 10 years¹ and 5-year survival rates continue to be less than 10%^{2,3}. Strategies successfully employed in other cancers, such as inhibiting mutated oncogenic drivers in the RTK-Ras-Raf pathway, have shown very little efficacy^{4,5}. Additionally, immunotherapeutic agents such as checkpoint inhibitors have achieved some benefit in patients with germline mismatch repair deficiencies⁶ but have had minimal success in patients whose tumors do not harbor mismatch repair deficiencies^{6,7}. These challenges can partly be explained by the low mutational rate of glioblastomas compared to epithelial malignancies, such as lung, bladder, endometrial or colorectal carcinomas⁸. Lastly, when oncogenic mutations are present, they often exhibit intra-tumoral heterogeneity⁹. For example, single-cell sequencing analysis of glioblastomas revealed that multiple activating mutations in *EGFR* can be found within the same tumor as part of different subclones, which may explain the lack of response or resistance to tyrosine kinase inhibitors¹⁰.

Interestingly, while many activated oncogenes in glioblastoma are subclonal, *TERT* promoter mutations commonly occur as clonal events^{11,12}. *TERT* promoter mutations were discovered in melanoma¹³ and later found in up to 80% of *IDH*-wildtype glioblastomas^{14,15}. These mutations are thought to be responsible for oncogenic re-activation of telomerase, a reverse transcriptase ribonucleoprotein complex that maintains telomere length in cells with high replicative potential^{16,17}. Without telomerase, cells have a finite number of divisions before telomere erosion and deprotection occurs, with activation of the DNA damage response pathway and induction of senescence and apoptosis^{18,19}. *TERT* promoter mutations result in transition of cytidine to

thymidine and occur most frequently at two “hotspot” loci, named c.-124 and c.-146C, upstream of the transcriptional start site¹³. Transcriptional activation was found to occur by recruiting the E26-transformation-specific (ETS) family transcription factor GA-binding protein (GABP)²⁰, which selectively binds to the mutant *TERT* promoter.

Given that *TERT* promoter mutations are frequent and among the few clonal oncogenic events in glioblastoma, we hypothesized that telomerase inhibition will be detrimental to the survival of tumor cells. Even before the *TERT* promoter mutations were discovered, telomerase was explored as an anti-cancer target because it is expressed in tumors but not most somatic cells²¹. The presence of *TERT* promoter mutations further strengthens the idea that telomerase expression in cancer is an active process rather than simply a marker of immortality. Multiple studies have analyzed cellular responses to short telomeres in normal cells through the use of transgenic mouse models^{19,22,23}. In addition, there have been several studies that explored the effects of telomerase ablation in cancer cells. Early studies, using a dominant negative form of telomerase²⁴ and anti-telomerase modified oligomers²⁵, have shown that telomerase loss is detrimental to cancer cells. In transgenic mice, T-cell lymphomas on a telomerase-null background display a less aggressive phenotype with lower penetrance and longer latency than control tumors from telomerase wild-type mice, however they eventually resume growth through activation of the alternative telomere lengthening (ALT) pathway²⁶. In glioblastoma, loss of the β 1L isoform of the GABP transcription factor that drives *TERT* expression leads to cell death in *TERT* promoter-mutant cells in a telomerase dependent manner²⁷. Most recently, *TERT* promoter mutation correction using programmable base editing was shown to lead to decreased proliferation, telomere length reduction and senescence in glioblastoma cells, both *in vitro* and *in vivo*²⁸.

148

149 In this study, we used CRISPR interference (CRISPRi) to demonstrate that telomerase ablation
150 can lead to cell lethality in *TERT* promoter-mutant glioblastoma cells, both *in vitro* and *in vivo*.
151 This occurs over several cell divisions required to cause telomere dysfunction, with telomere
152 shortening and formation of chromatin bridges. Additionally, we utilize an inducible CRISPRi
153 system to demonstrate that *in vivo* therapeutic efficacy is only achieved when telomerase
154 expression is turned off early in the tumorigenic process. These results highlight the importance
155 of selecting a patient population with low tumor burden when considering potential clinical
156 applications of telomerase inhibitors.

157

Materials and Methods

Plasmids

Plasmids used in this study include newly described plasmids including pRDA355 (Addgene # pending), and pLV407 (Addgene # pending), as well as previously described plasmids including pLX_311-KRAB-dCas9 (Addgene plasmid #96918), pLenti-dCas9_KRAB-MeCP2²⁹, pXPR_023d (in press), lentiGuide-Puro (Addgene plasmid # 52963), and px458 (Addgene plasmid # 48138).

Cell culture

LN18, T98G and SF295 glioblastoma cells were obtained from ATCC in December 2019 and genotyped using short tandem repeat analysis. The most recent date of *Mycoplasma* testing was 9/29/2021 for T98G and SF295 and 11/2/22 for LN18, and results were negative. Cells were cultured in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin. CPDM0095 and BT112 glioblastoma neurospheres were obtained from the Dana Farber Center for Patient Derived Models. Most recent date of mycoplasma testing was 3/22/22 and results were negative. Cells were cultured in Neural Stem Cell media supplemented with epidermal growth factor at 20 ng/mL, fibroblast growth factor at 20 ng/mL and 0.2% heparin.

Genotyping

Genomic DNA was extracted from glioblastoma cell lines LN18, T98G, SF295, CPDM0095 and BT112. PCR was performed using the primers annotated in Supplementary Table 1. The products were then sequenced using Sanger sequencing.

CRISPR interference

Transcriptional silencing using CRISPR interference (CRISPRi) was performed as previously described³⁰. Cells were first transduced with pLX_311-KRAB-dCas9 or Lenti_dCas9-KRAB-MeCP2³¹ for *in vivo* studies. Cells expressing these constructs were then transduced with pXPR_003 harboring short guide RNAs (sgRNAs) targeting *TERT* exon 1 (sgTERTe) or the *TERT* promoter (sgTERTp) (Figure 1B), or as controls, the hypoxanthine phosphoribosyltransferase 1 (*HPRT1*) promoter or a non-coding region of chromosome 2 (sgCh2.4). For inducible CRISPRi, cells expressing dCas9-KRAB-MeCP2 were transduced with pRDA355 harboring sgTERTe. For rescue experiments, cells were first transduced with pLV407 lentiviral vectors encoding either GFP or TERT. They were then transduced with pXPR_023d harboring sgRNA sgCh2.2 as well as sgTERTe were used (Supplementary Table 1).

Generation of *TERT*-knockout clones using CRISPR/Cas9

T98G cells were transfected with the px458 plasmid harboring sgRNAs targeting *TERT* exon 2 or the *AAVS1* locus (Supplementary Table 1). GFP-positive cells were isolated using fluorescence-activated cell sorting (FACS) and seeded into 96-well plates. Clones were then expanded and the CRISPR target region was amplified using PCR (Supplementary Table 1); amplicons showing evidence of genomic editing based on gel electrophoresis were then sequenced using next generation sequencing (Illumina paired-end sequencing). Analysis of next generation sequencing results was done using the NGS Genotyper v1.4.0.

Real-Time PCR

Knockdown efficiency was validated using real-time PCR. Total RNA was extracted from cells and 1 µg of RNA was used for the reverse transcriptase reaction. Real time PCR products were detected using SYBR green dye and primers targeting *TERT*, *HPRT* as well as actin (*ACTB*) and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) as controls (see Supplementary Table 1 for sequence information).

Colony formation assays

Two-dimensional colony formation assays were performed by seeding 8000 cells/well as 3 technical replicates in a 6-well plate. After 8-10 days, the cells were fixed and stained as previously described³². They were first washed with phosphate-buffered saline (PBS), then fixed in a solution of 4% paraformaldehyde in PBS for 15 minutes, then stained in a solution of 0.2% crystal violet, 2% ethanol for 30 minutes. Dye extraction was performed by adding 2 mL of 10% acetic acid solution to the fixed and stained cells and incubating for 20 minutes. Quantification was then performed by measuring absorbance at 580 nm.

Growth curve generation

TERT-knockout T98G clones and control clones were seeded at a density of 40,000 cells/well in a 24-well plate. The following day, they were transferred to the Incucyte chamber and images were taken every 6 hours (25 images per well). Growth curves were plotted using the Incucyte software based on percent confluency.

Cell cycle analysis

Cells were seeded at a density of 250,000 cells/well in 6-well plates. The next day, they were trypsinized and fixed in cold 70% ethanol for 2 hours. They were then washed with PBS and resuspended in a staining solution of 100 µg/mL RNase A and 50 µg/mL propidium iodide in PBS; incubation was for 30 minutes at 37 °C. Data was collected using a Beckman CytoFLEX flow cytometer (5,000 events per sample) and analyzed using FloJo.

Chromatin bridge analysis

Cells were trypsinized and seeded on silicone-based coverslips in a 6-well plate at a density of 200,000 cells/well. The following day, they were fixed in a solution of 4% paraformaldehyde in PBS for 15 minutes and stained using 4',6-diamidino-2-phenylindole (DAPI). Images were captured on a Nikon Ti-E inverted microscope with an Andor CSU-X1 spinning disc confocal system using a 60x oil immersion objective. For each condition, 10 separate fields were photographed, and the number of chromatin bridges were counted in each field by two independent observers.

Protein expression analysis by immunoblotting

Protein lysates were prepared using CHAPS lysis buffer supplemented with protease inhibitor (Millipore Sigma 11697498001) and 2.5 mM MgCl₂. 50 µg of protein were loaded for each sample and transferred to a PVDF membrane (Millipore Sigma IPVH00010). The following antibodies were used: anti-TERT (Rockland 600-401-252S), anti-PARP (Cell Signaling Technologies #9532), anti-cleaved PARP (Cell Signaling Technologies #5625) and anti-actin (Cell Signaling Technologies #4967). Secondary antibodies included goat anti-rabbit (LI-COR Biosciences 926-32211) and goat anti-mouse (LI-COR Biosciences 926-68020).

249 Telomere length measurements

250 Telomere length was measured using the Telo TTAGGG Telomere Length Assay (Millipore
251 Sigma 12209136001), based on telomere restriction fragment analysis³³. Briefly, genomic DNA
252 was extracted from cells and 1.5 µg of DNA was digested using *HinFI* and *RsaI*. Digestion
253 products were separated using agarose gel electrophoresis (0.8% agarose in TAE buffer),
254 transferred overnight onto a nylon membrane using capillary action in 20X SSC buffer, and
255 crosslinked using ultraviolet light. Hybridization was performed for 3 hours using a digoxigenin-
256 linked telomere probe. The membrane was then incubated in a solution containing anti-digoxigenin
257 antibody fragments linked to alkaline phosphatase. Luminescence signal was generated using the
258 CDP-*Star* chemiluminescence substrate and detected using a chemiluminescence scanner.
259 Developed films were scanned and quantified using Fiji (ImageJ).

260

261 Intracranial mouse injections

262 Animal studies were performed in compliance with guidelines and regulation of the Broad Institute
263 Institutional Animal Care and Use Committee (IACUC). 6-week-old female NOD-*scid*
264 ILRgamma^{null} (NSG) mice weighing between 15 and 20 grams were purchased from The Jackson
265 Laboratory. Intracranial tumor cell injections were performed as previously described²⁷. Mice were
266 anesthetized using isoflurane until not responsive to pinch reflex test. After preparing the surgical
267 field, a 1 cm skin incision was made in the scalp and the skull was penetrated using a drill with a
268 1.4 mm burr, 2 mm to the right of the bregma, directly posterior to the right suture. The needle
269 was then inserted at 2 mm depth and 300,000 cells in 2 µL of PBS were injected. The injection
270 was performed over 1 minute and the needle was kept in place for 1 minute after injection. The
271 surgical site was closed by suturing with 4-0 monofilament sutures. Perioperative care included

subcutaneous injection of 1 mg/kg buprenorphine directly after the procedure and 3 daily subcutaneous doses of 1 mg/kg meloxicam starting on the day of surgery. Animals were euthanized once they met humane endpoints of lethargy, neurological symptoms, or weight loss of 20% from initial weight. For doxycycline inducible experiments, T98G cells harboring Lenti_dCas9-KRAB-MeCP2 as well as inducible sgTERTe were injected intracranially in mice. Animals in the control group received regular feed, while animals in the experimental group received feed supplemented with doxycycline at 625 ppm.

Tumor imaging

Animals were anesthetized with isoflurane and received intraperitoneal injections of 150 mg/kg luciferin. They were then placed in the imaging chamber of the Perkin Elmer in vivo imaging system (IVIS) and bioluminescent images were captured. Luminescence was quantified using the Living Image software.

Statistical analysis

Statistical methods were not used to predetermine sample size. Data in all graphs shown is presented as the mean of independent biological or technical replicates as indicated in the figure legends and error bars represent standard deviations. For Figures 1C, D, F, Figure 2D, Figure 3A and B, and Figure 4D, H and J (bioluminescence curves), Supplementary Figure 3B, D and Supplementary Figure 5 *p*-values were calculated using the unpaired *t* test (GraphPad Prism 9). In Figures 4E, I and K and Supplementary Figure 7C (survival curves), survival analysis was performed using the Kaplan-Meier method and *p*-values were calculated using the Log-rank test (GraphPad Prism 9).

Results

Telomerase loss halts proliferation of *TERT* promoter-mutant glioblastoma cells *in vitro*.

We selected *TERT* promoter-mutant glioblastoma cell lines T98G and SF295 and *TERT* promoter-wildtype LN18 cells for this study. We also selected glioblastoma patient-derived neurospheres BT112 and CPDM0095. LN18 was confirmed to be *TERT* promoter wildtype, T98G and SF295 were confirmed to be heterozygous for the c.-146C>T and c.-124C>T mutations, respectively, and BT112 and CPDM0095 were found to be heterozygous for the c.-124C>T mutation using Sanger sequencing (Supplementary Figure 1). We then measured telomere length in these cell lines using the Telomere Restriction Fragment (TRF) assay³³ (Figure 1A) and found that the average telomere length is 4.1 Kb for T98G, 3.7 Kb for SF295, 5.2 Kb for BT112, 5.4 Kb for CPDM0095 and 4.0 Kb for LN18. We then applied CRISPR interference³⁰ to inhibit expression of the telomerase protein TERT in cell lines T98G, SF295 and LN18. Two different sgRNAs were used, sgTERTe targeting *TERT* exon 1 and sgTERTp targeting the *TERT* promoter (Figure 1B), leading to reduction in *TERT* mRNA levels of >70% for the *TERT* promoter-mutant lines and >50% for LN18 (Figure 1C). Two sgRNAs were used as control, sgCh2.4, targeting a non-coding region on chromosome 2, as well as sgHPRT1, targeting the promoter of *HPRT1*, which is not known to be an essential gene for cell survival. *TERT* knockdown led to a decrease in proliferation manifesting over a period of 69 days for T98G and 65 days for SF295. We did not detect a significant reduction in proliferation for LN18 cells over a period of over 64 days (Figure 1D). T98G and SF295 cell lines harboring sgTERTe or sgTERTp eventually restored *TERT* expression (Supplementary Figure 2A) by decreasing Cas9 expression, restoring viability and proliferative capacity comparable to control cells with *HPRT1* knockdown (Supplementary Figure 2B), which in contrast retained Cas9 expression and HPRT1 loss (Supplementary Figure 2C). The restoration of survival

and proliferation by loss of Cas9 expression supports the idea that telomerase-null cells are under negative selective pressure. We validated these results using glioblastoma patient-derived neurosphere CPDM0095. CPDM0095 cells harboring sgTERTe exhibited a reduction in *TERT* mRNA levels of >90% compared to cells harboring sgCh2.2 (Figure 1E). These cells also exhibit a loss of proliferation over a period of 50-80 days (Figure 1F).

To further validate the effect of *TERT* knockdown on proliferation in a clonal rather than polyclonal populations, we generated T98G single cell clones harboring homozygous frameshift edits in *TERT* exon 2 using CRISPR/Cas9. We identified 2 clones with frameshift edits in *TERT* exon 2 corresponding to the CRISPR sgRNA binding site (Supplementary Figure 3A). *TERT*-edited clones proliferated at a lower rate when compared to control clones (Supplementary Figure 3B). These results further support the conclusion that telomerase is essential for cell survival in *TERT* promoter-mutant glioblastoma cells.

To verify whether the viability defect caused by anti-*TERT* sgRNAs in T98G and SF295 cells was due to reduction of *TERT* expression, we asked whether ectopic expression of *TERT* would rescue this growth defect. We ectopically expressed GFP and *TERT* in T98G and SF295 cells (Figure 2A). This ectopic expression led to a significant increase in *TERT* mRNA levels even when the TERTe sgRNA was also expressed (Figure 2B). When we attempted to assess *TERT* protein levels by immunoblotting, we saw a band at approximately 125 kDa only in the cells with *TERT* overexpression (Figure 2C). This result indicates that *TERT* ectopic expression was successful and endogenous *TERT* protein is not detectable by immunoblot in T98G and SF295 cells under our experimental conditions. Next, we used crystal violet staining of colony formation to assess the

proliferation status of T98G and SF295 cells transduced with sgTERTe and the sgCh2.2 control. Overexpression of wild type TERT in both T98G and SF295 cells rescued the proliferation defect induced by sgTERTe (Figure 2D).

Telomerase-null glioblastoma cells exhibit telomere shortening and evidence of telomere dysfunction.

To understand the mechanism of proliferation arrest in telomerase-deficient glioblastoma cells, we measured telomere length using the TRF assay. We measured telomere length 46 days after *TERT* knockdown in control and telomerase-deficient cells. We found that the average telomere length of *TERT*-knockdown cells was on average ~900 base pairs shorter than the controls for T98G and ~700 base pairs shorter than the controls for SF295 (Figure 3A). Similarly, *TERT*-edited single cell clones had shorter telomere length compared to control clones (Supplementary Figure 3C). Short telomeres are known to cause growth arrest by senescence, apoptosis, or telomere crisis, and telomere crisis is known to occur in the absence of a functioning p53 pathway^{38,39,40,41}. Alterations in the p53 pathway are frequent in glioblastomas, occurring in up to 85% of cases through *TP53* mutations, *CDKN2A* deletion and *MDM1/2/4* amplification⁴². Both T98G and SF295 cells carry *TP53* loss of function mutations (Supplementary Figure 4A) as well as homozygous *CDKN2A* deletions. Upon telomere shortening and growth arrest, we did not observe an increase in apoptosis markers by immunoblot (Supplementary Figure 4B). We found that telomerase-deficient cells undergo cell cycle arrest, with an accumulation of cells in the S or G2/M phases of the cycle, a phenotype that was pronounced in *TERT*-deficient T98G clones (Supplementary Figure 3D) but not in cell populations treated with CRISPR interference (Supplementary Figure 5). This

difference may be due to the fact that the population of cells treated with CRISPR interference is more heterogeneous than in the clones.

Regarding the mechanism of cell death induced by telomere shortening, on the chromosomal level, we observed a significant increase in chromatin bridges in telomerase-deficient cells compared to control cells (Figure 3B). Chromatin bridges are thought to occur from fusions between dysfunctional telomeres that have become deprotected and have been described as precursors to catastrophic genomic events in telomere crisis, including chromothripsis and katagenesis⁴¹. Together, these findings suggest that upon telomerase ablation, glioblastoma cells undergo telomere crisis.

Telomerase inhibition *in vivo* prolongs survival only when induced in the low tumor burden setting.

To further validate telomerase dependency in glioblastoma, we generated luciferase-expressing *TERT*-knockdown and control T98G cell populations and performed intracranial xenograft injections into immunocompromised mice (Figure 4A). We allowed cells to proliferate *in vitro* for 30 days before injecting them into mice. Shortly before implantation, *TERT* mRNA levels were reduced by >99% in *TERT*-knockdown cells compared to controls, and their average telomere length was 3.7 Kb for control cells and 2.9 Kb for *TERT*-knockdown cells (Figure 4B). We observed a significant reduction in tumor forming abilities in *TERT*-knockdown cells, which did not form intracranial tumors in over 60 days (Figures 4C,D). This in turn led to significantly prolonged survival for animals injected with telomerase-deficient cells versus controls (Figure 4E). It is possible that the reduction in tumor-forming abilities of *TERT*-knockdown cells was due to

telomere shortening that took place while the cells were proliferating in culture prior to implantation, rather than by the impact of loss of telomerase activity after implantation. We then sought to determine the degree of tumor burden that would be required to achieve a therapeutic benefit from telomerase inhibition. For this purpose, we generated an inducible CRISPRi system using sgTERTe, which successfully suppressed TERT expression in vitro (Supplementary Figure 6). We then performed intracranial xenograft injections of T98G cells harboring the inducible CRISPRi system. We divided our animals in two cohorts, one where we started doxycycline feeding 40 days post-surgery and one where we started doxycycline on the day of surgery (Figure 4F). We found that *in vivo* TERT expression was successfully suppressed (Figure 4G). While there was no statistically significant difference in intracranial luminescence in animals treated with doxycycline at day 40 (Figure 4H), we detected a significant difference in intracranial luminescence 73 days after tumor implantation in animals treated at day 0 (Figure 4J). Similarly, we detected a survival benefit only for the group that received doxycycline at day 0 (Figures 4I,K). In a follow up experiment, we administered doxycycline feed at additional intermediate timepoints (days 10 and 25) (Supplementary Figure 7A). We did not observe a significant difference in intracranial luminescence signal between the groups (Supplementary Figure 7B), and we only observed a statistically significant prolongation in survival for animals that were treated at days 0 and 10 (Supplementary Figure 7C). Longer-term follow-up suggests a significant survival advantage for a subset of mice treated with doxycycline to induce TERT silencing. There were no long-term surviving mice in a 200-day experiment, in the group without doxycycline induction of TERT silencing. In contrast, after 200 days of doxycycline treatment, there were three surviving mice in the group that was treated with doxycycline at day 0 of implantation (Figure 4K) as well as three surviving mice in the group that was treated with doxycycline at day 40 of implantation

(Figure 4I). In addition, there were 2 mice in the day 0 and day 10 induction arms, as well as 1 mouse in the day 25 induction arm, still surviving at day 100 in the follow up experiment (Supplementary Figure 7C). Overall, these results suggest that the most appropriate clinical setting for the deployment of a telomerase inhibitor might be for glioblastoma patients with low tumor burden, but a subset of patients with high tumor burden may benefit as well, if the human disease would recapitulate the observations seen in this mouse orthotopic model.

Discussion

Glioblastoma is among the deadliest of all cancers, with a median duration of survival of only 14 months¹. In the past decade, there has been significant progress in understanding the genomic landscape of glioblastoma, and glioblastomas were among the first tumors to be studied in The Cancer Genome Atlas project (TCGA)⁴². Despite these advances, standard therapeutic options have not changed significantly since 2005, when the addition of the alkylating agent temozolomide to radiation therapy was found to confer an overall survival benefit of 2.6 months for all patients¹ and 6.4 months for patients whose tumors harbor methylation at the *MGMT* promoter⁴³. Clinical trials of targeted therapeutics aimed towards mutant and amplified oncogenic drivers have shown very little benefit^{4,5}. These results can be explained by a unique feature of glioblastomas, which is their genomic heterogeneity as evidenced by independent amplifications of multiple oncogenic driver genes in distinct tumor cells⁹ or by multiple activating mutations of the same driver gene in distinct tumor cells¹⁰.

In contrast, multiple studies have reported that *TERT* promoter mutations are the most common clonal activating mutations in glioblastoma¹¹. The *TERT* promoter mutations are therefore thought to arise early in tumor evolution¹¹. For this reason, *TERT* promoter mutations could provide a unique therapeutic opportunity with a lower probability of exhibiting intrinsic resistance from intra-tumoral heterogeneity. Prior studies have demonstrated that silencing the *TERT* promoter by CRISPR-mediated ablation of the GABP transcription factor²⁷, or by correction of *TERT* promoter mutations using base editing²⁸ is deleterious to glioblastoma cells. In this study, we silenced the *TERT* promoter using CRISPR interference. This method leads to reliable and substantial reduction

of *TERT* mRNA levels. CRISPR interference can be helpful to understand the effects of telomerase loss in a population of cells rather than individual knockout clones. Its advantage over traditional CRISPR editing is that the degree of knockdown can be readily measured and followed using real-time PCR. This is particularly useful when studying telomerase since TERT protein levels are challenging to detect due to low endogenous expression in cells⁴⁴. The limitation of CRISPR interference relative to *TERT* knockout clones is that telomerase null cells are gradually lost in the population over cells with wildtype *TERT* expression and low Cas9 expression. The phenotype of cells in telomere crisis is therefore more pronounced in *TERT* knockout clones, which are a more appropriate model to perform mechanistic evaluations of cell lethality.

We found that TERT loss in *TERT* promoter-mutant glioblastoma cells leads to a reduction in cell viability associated with features of telomere crisis, including the formation of chromatin bridges and cell cycle arrest. This suggests that telomerase is not only an important driver of glioma initiation, but it is also key for tumor maintenance, raising the possibility that telomerase targeted therapeutics may be effective at treating this deadly cancer. An important limitation of telomerase inhibitors as anti-cancer therapeutics is that cell death upon telomerase loss does not occur immediately but requires several cell divisions. Before considering this strategy, it is therefore crucial to demonstrate whether telomerase inhibition can offer a therapeutic benefit *in vivo*, and if so in what specific clinical setting. With this study, we showed that telomerase loss does not lead to a survival benefit in animals with high tumor burden, but it provides a significant benefit in the low tumor burden setting. Here, we should mention the limitation that our current animal model data represent only the study of a single cell line, albeit under many experimental conditions. This supports the idea that telomerase inhibitors could be employed in the adjuvant setting, when tumor

debulking has recently occurred and tumor burden is low. A recent study showing that telomerase loss sensitizes glioblastoma cells to DNA damage²⁰ further supports the idea that telomerase inhibitors could be offered to glioblastoma patients in conjunction with adjuvant temozolomide.

In conclusion, with this study we describe the results of *TERT* knockdown in a population of cells using CRISPR interference. Using this approach, we showed that *TERT* promoter-mutant glioblastoma cells are dependent on telomerase and exhibit classic features of telomere crisis upon telomerase loss. Using orthotopic xenograft models, we also showed that only animals with low tumor burden achieve a survival benefit from telomerase inhibition. These results support the value of pre-clinical and eventually clinical investigations of anti-telomerase compounds to treat glioblastoma, and they help in the identification of the patient population that would most benefit from this therapeutic strategy.

Funding: E.A. is the Ben and Catherine Ivy Foundation Physician-Scientist of the Damon Runyon Cancer Research Foundation (PST-28-20). The Baird laboratory was supported by Cancer Research UK (A18246/A29202) and the Wales Cancer Research Centre.

Acknowledgements: We thank Andrew Allen for technical assistance with the confocal microscope at the Broad Institute. We thank Dr. Douglas Wheeler, Dr. Gizem Uzumbas and Dr. Charlie Lee for insightful discussion. We thank Dr. Tsukasa Shibue for plasmid pXPR_023D.

References

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* Mar 10 2005;352(10):987-96. doi:10.1056/NEJMoa043330
2. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro Oncol.* Aug 17 2020;22(8):1073-1113. doi:10.1093/neuonc/noaa106
3. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol.* Nov 1 2019;21(Suppl 5):v1-v100. doi:10.1093/neuonc/noz150
4. Raizer JJ, Giglio P, Hu J, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. *J Neurooncol.* Jan 2016;126(1):185-192. doi:10.1007/s11060-015-1958-z
5. Reardon DA, Nabors LB, Mason WP, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. *Neuro Oncol.* Mar 2015;17(3):430-9. doi:10.1093/neuonc/nou160
6. Bouffet E, Larouche V, Campbell BB, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *J Clin Oncol.* Jul 1 2016;34(19):2206-11. doi:10.1200/JCO.2016.66.6552
7. Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. *JAMA Oncol.* Jul 1 2020;6(7):1003-1010. doi:10.1001/jamaoncol.2020.1024
8. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. *Nature.* Oct 17 2013;502(7471):333-339. doi:10.1038/nature12634
9. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. *Cancer Cell.* Dec 13 2011;20(6):810-7. doi:10.1016/j.ccr.2011.11.005
10. Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. *Cancer Discov.* Aug 2014;4(8):956-71. doi:10.1158/2159-8290.CD-13-0879
11. Korber V, Yang J, Barah P, et al. Evolutionary Trajectories of IDH(WT) Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. *Cancer Cell.* Apr 15 2019;35(4):692-704 e12. doi:10.1016/j.ccell.2019.02.007
12. Brastianos PK, Nayyar N, Rosebrock D, et al. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. *NPJ Precis Oncol.* 2017;1(1):33. doi:10.1038/s41698-017-0035-9
13. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. *Science.* Feb 22 2013;339(6122):957-9. doi:10.1126/science.1229259
14. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci U S A.* Apr 9 2013;110(15):6021-6. doi:10.1073/pnas.1303607110
15. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. *Nat Commun.* 2013;4:2185. doi:10.1038/ncomms3185

16. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. *Nature*. Jan 26 1989;337(6205):331-7. doi:10.1038/337331a0
17. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell*. Aug 22 1997;90(4):785-95. doi:10.1016/s0092-8674(00)80538-3
18. AS IJ, Greider CW. Short telomeres induce a DNA damage response in *Saccharomyces cerevisiae*. *Mol Biol Cell*. Mar 2003;14(3):987-1001. doi:10.1091/mbc.02-04-0057
19. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature*. Nov 13 2003;426(6963):194-8. doi:10.1038/nature02118
20. Amen AM, Fellmann C, Soczek KM, et al. Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. *Proc Natl Acad Sci U S A*. Mar 30 2021;118(13)doi:10.1073/pnas.2008772118
21. Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. *Ann Med*. Mar 2001;33(2):123-9. doi:10.3109/07853890109002067
22. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. *Nature*. Apr 9 1998;392(6676):569-74. doi:10.1038/33345
23. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell*. Oct 3 1997;91(1):25-34. doi:10.1016/s0092-8674(01)80006-4
24. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. *Nat Med*. Oct 1999;5(10):1164-70. doi:10.1038/13495
25. Herbert B, Pitts AE, Baker SI, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. *Proc Natl Acad Sci U S A*. Dec 7 1999;96(25):14276-81. doi:10.1073/pnas.96.25.14276
26. Hu JH, S. S.; Liesa, M.; Gan, B.; Sahin, E.; Jaskelioff, M.; Ding, Z.; Ying, H.; Boutin, A.; Zhang, H.; Johnson, S.; Ivanova, E.; Kost-Alimova, M.; Protopopov, A.; Wang, A.; Shirihai, O. S.; Chin, L.; DePinho, R. Anti-telomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. *Cell*. Feb 17 2012;148(4):651-663.
27. Mancini A, Xavier-Magalhaes A, Woods WS, et al. Disruption of the beta1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. *Cancer Cell*. Sep 10 2018;34(3):513-528 e8. doi:10.1016/j.ccell.2018.08.003
28. Li X, Qian X, Wang B, et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. *Nat Cell Biol*. Mar 2020;22(3):282-288. doi:10.1038/s41556-020-0471-6
29. Liu Y, Wu Z, Zhou J, et al. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. *Nat Commun*. Dec 8 2021;12(1):7139. doi:10.1038/s41467-021-27055-4
30. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. *Nat Protoc*. Nov 2013;8(11):2180-96. doi:10.1038/nprot.2013.132
31. Yeo NC, Chavez A, Lance-Byrne A, et al. An enhanced CRISPR repressor for targeted mammalian gene regulation. *Nat Methods*. Aug 2018;15(8):611-616. doi:10.1038/s41592-018-0048-5

32. Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. *Science*. Oct 9 2015;350(6257):211-7. doi:10.1126/science.aaa4903
33. Mender I, Shay JW. Telomere Restriction Fragment (TRF) Analysis. *Bio Protoc*. Nov 20 2015;5(22)doi:10.21769/bioprotoc.1658
34. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. Jan 1 2013;29(1):15-21. doi:10.1093/bioinformatics/bts635
35. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods*. Apr 2017;14(4):417-419. doi:10.1038/nmeth.4197
36. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
37. Cornwell M, Vangala M, Taing L, et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. *BMC Bioinformatics*. Apr 12 2018;19(1):135. doi:10.1186/s12859-018-2139-9
38. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell*. May 14 1999;97(4):527-38. doi:10.1016/s0092-8674(00)80762-x
39. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. *Science*. Jul 26 2002;297(5581):565-9. doi:10.1126/science.297.5581.565
40. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. *EMBO J*. Aug 15 2002;21(16):4338-48. doi:10.1093/emboj/cdf433
41. Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and Kataegis Induced by Telomere Crisis. *Cell*. Dec 17 2015;163(7):1641-54. doi:10.1016/j.cell.2015.11.054
42. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. *Cell*. Oct 10 2013;155(2):462-77. doi:10.1016/j.cell.2013.09.034
43. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*. Mar 10 2005;352(10):997-1003. doi:10.1056/NEJMoA043331
44. Xi L, Schmidt JC, Zaug AJ, Ascarrunz DR, Cech TR. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. *Genome Biol*. Nov 10 2015;16:231. doi:10.1186/s13059-015-0791-1

Figure Legends:

Figure 1: (A.) Average telomere length of *TERT* promoter-mutant glioblastoma cell lines T98G and SF295 and glioblastoma neurospheres BT112 and CPDM0095, as well as *TERT* promoter-wildtype cell line LN18. (B) Two sgRNAs targeting the *TERT* locus: sgTERTp binds to the *TERT* promoter and sgTERTe binds to *TERT* exon 1. (C.) Relative *TERT* and *HPRT* mRNA expression after CRISPR interference treatment of T98G, SF295 and LN18 cells. Two biological replicates were used. (D) Crystal violet-stained plates (left panel) and proliferation curves (right panel) of CRISPR interference-treated T98G, SF295 and LN18 cells. Illustrated plates were stained 69, 65 and 64 days after transduction with sgRNAs for T98G (upper panel) SF295 (middle panel) and LN18 (lower panel), respectively. Three technical replicates were used, and the experiment was repeated for validation. (E) Relative *TERT* mRNA expression for CPDM0095 treated with sgTERTe versus sgCh2.2. Four technical replicates were used. (F.) Representative images of CPDM0059 cells harboring sgCh2.2 and sgTERTe 69 days post-transduction (left panel) and proliferation curve (right panel). Scale bars represent 1 mm. Two biological replicates were used.

* = $p < 0.05$, ** = $p < 0.005$, **** = $p < 0.0001$

Figure 2: (A) Design of rescue experiments. (B) Real time qRT-PCR analysis of *TERT* mRNA levels in sgCh2.2-treated and sgTERTe-treated T98G and SF295 cells, with ectopic GFP expression (left) or ectopic TERT expression (right). (C.) Immunoblot with anti-TERT antibody 600-491-252 (D.) Normalized 580 nm absorbance of crystal violet-stained plates seeded with GFP-expressing T98G and SF295 cells harboring sgCh2.2 vs. sgTERTe (left) or TERT-expressing cells harboring sgCh2.2 vs. sgTERTe (right). Colony formation assays were stained 32 and 35 days

after transduction with sgRNAs for T98G and SF295 cells, respectively. Three technical replicates were used, and experiment was repeated for validation. ** = $p < 0.005$, *** = $p < 0.001$.

Figure 3: (A) Telomere restriction fragment (TRF) analysis of SF295 and T98G glioblastoma cells with and without *TERT* knockdown, performed 46 days after induction of knockdown. Two technical replicates were used for this analysis. (B) Representative images showing chromatin bridges in *TERT*-knockdown T98G and SF295 cells. Scale bars represent 2.17 μm . (C) Quantification of chromatin bridges in *TERT*-knockdown T98G and SF295 cells compared to controls. * = $p < 0.05$, ** = $p < 0.005$, *** = $p < 0.001$, **** = $p < 0.0001$

Figure 4: (A) Schematic diagram of *in vivo* xenograft experiments. (B) TRF analysis showing average telomere lengths of T98G cells treated with sgCh2.4 and sgTERTe prior to implantation into mice. (C) Representative image of intracranial luminescence of animals harboring control and *TERT*-knockdown T98G cells; images were taken 55 days after tumor implantation. (D) Serial measurements of intracranial luminescence of animals harboring control and sgTERTe-treated T98G cells. (E) Kaplan-Meier curve showing overall survival of animals harboring sgTERTe-treated T98G cells compared to mice harboring control cells. (F) Schematic of *in vivo* experiment using a doxycycline inducible CRISPR interference system. (G) Relative *TERT* mRNA expression of intracranial tumors of animals treated with doxycycline feed versus control feed. (H) Serial measurements of intracranial luminescence of animals treated with doxycycline feed at day 40 post-surgery versus control feed. (I) Overall survival of animals treated with doxycycline feed at day 40 post-surgery versus control. (J) Serial measurements of intracranial luminescence of animals treated with doxycycline feed on the day of surgery versus control feed. (K) Overall

672 survival of animals treated with doxycycline feed on the day of surgery versus control feed. ** =
673 $p < 0.005$, **** = $p < 0.0001$, ns = non-significant.

674